Business
-
SpliSense announced that it has secured up to $13 million in new funding from the Cystic Fibrosis Foundation to support an ongoing Phase 2 trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic… Read more . . .
-
According to DPI developer Iconovo, the company has now signed a strategic collaboration deal with CDMO Lonza for development of spray dried formulation of inhaled biologics. In January 2025, Iconovo said that Lonza would develop spray dried… Read more . . .
-
Lupin Limited announced that it has partnered with Laboratorios ERN for the launch of Lupin’s Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Spain. Luforbec, a generic version of Chiesi’s… Read more . . .
-
Scienture Holdings, which acquired US rights to Summit Biosciences’s Rezenopy naloxone nasal spray in March 2025, announced that the United States Patent and Trademark Office has granted Summit US Patent No. 12,622,903 B2 covering Rezenopy… Read more . . .
-
Jiangxi Kvvit Pharmaceutical is paying an undisclosed amount up front, plus potential milestones and royalties, to Merz Therapeutics to acquire the rights to develop and commercialize Merz’s Inbrija levodopa dry powder inhaler in mainland China,… Read more . . .
-
Australian biotech Rage Bio, which has been developing an inhaled splice-switching oligonucleotide (SSO) for the treatment of COPD, has announced that it has changed its name to Atisama Therapeutics. According to the announcement, the name… Read more . . .
-
Quince Therapeutics announced that it has agreed to acquire Orphai Therapeutics (formerly AI Therapeutics, formerly LAM Therapeutics) and its LAM-001 inhaled dry powder rapamycin (sirolimus) for $115 million up front and up to an additional… Read more . . .
-
More than a year after the FDA approved Satsuma’s Atzumi (STS 101) intranasal dry powder dihydroergotamine for the treatment of migraine in adults, Satsuma parent company SNBL says that it is still trying to find… Read more . . .
-
Vertex has stopped a Phase 1/2 study of VX-522 inhaled RNA therapy for the treatment of cystic fibrosis and has ceased development of the product, the company said in its most recent report of financial… Read more . . .
-
MannKind Corporation announced that it is developing a DPI formulation of MNKD-1501 ralinepag for the treatment of pulmonary arterial hypertension under an agreement with United Therapeutics under a 2018 licensing and collaboration agreement between the companies that… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden